Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial

被引：0

作者：

Motzer, Robert J.

Penkov, Konstantin

Uemura, Hirotsugu

Campbell, Matthew T.

Kollmannsberger, Christian K.

Lee, Jae-Lyun

Venugopal, Balaji

Van Den Eertwegh, Alfonsus

Negrier, Sylvie

Gurney, Howard

Albiges, Laurence

Berger, Raanan

Haanen, John

Rini, Brian I.

Larkin, James

Schmidinger, Manuela

Sandner, Robin

Wang, Jing

Di Pietro, Alessandra

Choueiri, Toni K.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Private Med Inst, Euromed Serv, St Petersburg, Russia

[3] Kindai Univ, Dept Urol, Fac Med, Osaka, Japan

[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Genitourinary Med Oncol, Houston, TX USA

[5] British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[8] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[9] Univ Lyon, Lyon, France

[10] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia

[11] Inst Gustave Roussy, Villejuif, France

[12] Chaim Sheba Med Ctr, Ramat Gan, Israel

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] Royal Marsden Hosp NHS Fdn Trust, London, England

[16] Med Univ Vienna, Vienna, Austria

[17] Pfizer Inc, Collegeville, PA USA

[18] Pfizer Inc, Cambridge, MA USA

[19] Pfizer SRL, Milan, Italy

[20] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：1

共 50 条

[31] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Choueiri, T.
Larkin, J.
Albiges, L.
Haanen, J. B.
Schmidinger, M.
Atkins, M. B.
Mariani, M.
Shnaidman, M.
Di Pietro, A.
Rini, B. I.
ANNALS OF ONCOLOGY, 2016, 27
[32] C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
Tomita, Yoshihiko
Motzer, Robert J.
Choueiri, Toni K.
Rini, Brian I.
Uemura, Hirotsugu
Oya, Mototsugu
Albiges, Laurence
Fujii, Yosuke
Umeyama, Yoshiko
Huang, Bo
Di Pietro, Alessandra
Schmidinger, Manuela
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[33] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): Results from JAVELIN Renal 101
Grimm, M-O.
Oya, M.
Choueiri, T. K.
Schmidinger, M.
Quinn, D. I.
Mescam, G. Gravis
Verzoni, E.
Van den Eertwegh, A. J. M.
di Pietro, A.
Mariani, M.
Wang, J.
Thomaidou, D.
Albiges, L.
ANNALS OF ONCOLOGY, 2021, 32 : S690 - S691
[34] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101
Grimm, Marc-Oliver
Oya, Mototsugu
Choueiri, Toni K.
Schmidinger, Manuela
Quinn, David
Gravis-Mescam, Gwenaelle
Verzoni, Elena
Van den Eertwegh, Alfonsus
Di Pietro, Alessandra
Mariani, Mariangela
Wang, Jing
Thomaidou, Despina
Albiges, Laurence
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
[35] Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Motzer, Robert J.
Choueiri, Toni K.
Rini, Brian I.
Miyake, Hideaki
Oya, Mototsugu
Albiges, Laurence
Fujii, Yosuke
Umeyama, Yoshiko
Wang Jing
Di Pietro, Alessandra
Schmidinger, Manuela
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[36] Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
Larkin, James
Oya, Mototsugu
Martignoni, Marcella
Thistlethwaite, Fiona
Nathan, Paul
Ornstein, Moshe C.
Powles, Thomas
Beckermann, Kathryn E.
Balar, Arjun, V
McDermott, David
Gupta, Sumati
Philips, George K.
Gordon, Michael S.
Uemura, Hirotsugu
Tomita, Yoshihiko
Wang, Jing
Michelon, Elisabete
di Pietro, Alessandra
Choueiri, Toni K.
ONCOLOGIST, 2022, : 333 - 340
[37] Association of C-reactive protein (CRP) with efficacy of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
Tomita, Yoshihiko
Larkin, James
Venugopal, Balaji
Haanen, John B. A. G.
Kanayama, Hiro-Omi
Eto, Masatoshi
Grimm, Marc-Oliver
Fujii, Yosuke
Umeyama, Yoshiko
Mariani, Mariangela
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[38] Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
Rini, Brian I.
Escudier, Bernard
Murphy, Danielle
Wang, Panpan
Tarazi, Jamal Christo
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[39] Final Analysis of Post-Marketing Surveillance for Avelumab plus Axitinib in Patients With Renal Cell Carcinoma in Japan
Nonomura, Norio
Ito, Taito
Sato, Masashi
Morita, Makiko
Ogi, Mie
Kajita, Masahiro
Oya, Mototsugu
CANCER MEDICINE, 2025, 14 (02):
[40] Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Motzer, Robert J.
Powles, Thomas
Atkins, Michael B.
Escudier, Bernard
McDermott, David F.
Alekseev, Boris Y.
Lee, Jae-Lyun
Suarez, Cristina
Stroyakovskiy, Daniil
De Giorgi, Ugo
Donskov, Frede
Mellado, Begona
Banchereau, Romain
Hamidi, Habib
Khan, Omara
Craine, Veronica
Huseni, Mahrukh
Flinn, Nick
Dubey, Sarita
Rini, Brian, I
JAMA ONCOLOGY, 2022, 8 (02) : 275 - 280

← 1 2 3 4 5 →